Evidence map›Paper›PMID 41373803›Full record

ArticleInternational journal of molecular sciences2025

Development and In Vitro Evaluation of [

Hoda Talebian, Samia Ait-Mohand, Prenitha Mercy Ignatius Arokia Doss, Léon Sanche, Brigitte Guérin

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hoda TalebianDepartment of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Samia Ait-MohandDepartment of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Prenitha Mercy Ignatius Arokia DossDepartment of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Léon SancheDepartment of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.ORCID 0000-0003-0938-439X
Brigitte GuérinDepartment of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.ORCID 0000-0002-0319-4512

Funding

New Frontiers in Research Fund - Transformation NFRFT-2022-00269
6 · The paper itself

Abstract

Prostate cancer (PCa), particularly in its metastatic form, remains a major clinical challenge due to limited diagnostic and therapeutic options. To address this, we developed a novel radiotheranostic agent, [

Indexed as

Coordination ComplexesCopper RadioisotopesGlutamate Carboxypeptidase IIProstatic NeoplasmsPyridinesRadiopharmaceuticalsAntigens, SurfaceCell Line, TumorHEK293 CellsHumansMaleAntigens, SurfaceCoordination ComplexesCopper-64Copper RadioisotopesFOLH1 protein, humanGlutamate Carboxypeptidase IIPyridinesRadiopharmaceuticalscopper-64in vitro validationprostate cancerPSMAradiotheranostic agentterpyridine-platinum

Identifiers

PMID41373803
PMCPMC12692291

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.